The Steiner family, faced with an urgent challenge, is rallying support to secure a vital treatment for their son, Aiden, who has been diagnosed with a rare neurodegenerative illness known as Infantile Neuroaxonal Dystrophy (INAD). This condition threatens to dramatically shorten his life, with most affected children not surviving past the age of ten, a fact that weighs heavily on the hearts of his parents.
:max_bytes(150000):strip_icc():format(jpeg)/aiden-steiner1-020926-d58a4b1ff28441a59544ab0a6767a8e5.jpg)
Aiden, now eight years old, showed early signs of his condition when he began walking backwards at the tender age of five. His mother, Dana Steiner, an entertainment publicist, recalls the alarming incidents when Aiden fell and sustained injuries that required hospital treatment. Despite concerns, doctors initially dismissed the issues, attributing them to typical developmental phases. However, the family’s persistence led them to more thorough evaluations, revealing the tragic diagnosis in May 2024.
Dr. Jonathan Santoro, Aiden’s neurologist and head of the neurology department at Children’s Hospital Los Angeles, describes INAD as exceedingly rare, with fewer than 100 known cases worldwide. The disease is often likened to a combination of pediatric ALS and Parkinson’s, gradually robbing victims of their ability to walk, speak, and ultimately breathe. Upon learning the grim prognosis for Aiden, Dana describes her reaction as one of immediate disbelief, stating, “I blacked out.”
In light of the bleak outlook, the Steiner family established the AJS Foundation, a registered non-profit aimed at funding research and finding a cure for Aiden. With the unfortunate reality that rare diseases do not attract significant pharmaceutical investment, the family understands the necessity of grassroots fundraising. Their initiative has been met with overwhelming community support, having raised over £400,000 in just a year.
The foundation has teamed up with the INAD Cure Foundation in New Jersey, which is currently working on producing doses of a promising gene therapy. Dana emphasises the importance of this advancement, asserting that “gene therapy is no longer an experimental science; it is real and has the potential to save lives.” Moreover, she remains hopeful that a clinical trial could receive approval from the FDA in the upcoming spring.
In addition to community fundraising efforts, the Steiner family is actively pursuing grants and seeking to raise an additional £1.5 million to propel the clinical trial forward. Selling merchandise under “Aiden’s A-Team” has become one of their strategies to gather funds. As Dana states, “We’re not asking for a miracle, we’re asking for a chance. This is science. This works.”
Sadly, Aiden’s condition has been steadily deteriorating, with Dana expressing the heartache of “losing pieces” of him daily. He has begun to require assistance in mobility, transitioning from using leg braces to a walker, and will eventually need a wheelchair. Despite the challenges, Aiden continues to radiate positive energy and maintains a capacity for joy, as he engages in outdoor activities with his family, including adaptive skiing.
To ensure Aiden lives fully in the present, Dana is committed to creating enriching experiences for him, even if they differ from those he might have had before his diagnosis. This includes imaginative adaptations like using a wagon to carry him to the beach, or accompanying him on thrilling adventures in an adaptive ski programme. She treasures Aiden’s spirited nature, describing him as “the definition of happiness and joy.”
The family is trying to instill the importance of cherishing each moment in Aiden’s younger brother, Landon, imparting the message that Aiden may not always be there. Dana frequently contemplates the potential loss of their shared communications, such as the day Aiden may no longer be able to reply to her affectionate declarations.
As they navigate these challenging times, the Steiners remain steadfast in their hope for a future where medicine can successfully intervene in rare diseases like INAD. Dr. Santoro echoes this sentiment, stating a shift is happening in the field, suggesting that with the right resources and determination, there is potential for meaningful change in treatment prospects.
In summary, the Steiner family’s journey is a poignant reminder of the trials faced by those with rare diseases, the incredible resilience of hope, and the profound impact of community support in the fight for life-saving treatments.